Navigation Links
Cytel's Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
Date:6/23/2008

Trial design and implementation pioneers from Cytel join peers in examining

the rise of adaptive study approaches and overcoming the remaining

challenges to wider adoption

CAMBRIDGE, Mass., June 23 /PRNewswire/ -- Cytel's renowned adaptive trial design and implementation experts Cyrus Mehta (http://www.cytel.com) and Judith Quinlan (http://www.cytel.com) will lead workshops and case study reviews at the Annual Meeting of the Drug Information Association (DIA) June 22 - 25, 2008 in Boston.

Adaptive trials are finding ever-increasing acceptance by sponsors and regulators seeking to improve clinical development productivity and reduce the rate of trial failures. Combining a wealth of experience designing and implementing adaptive trials together with over 20 years developing software for trial design, simulation and analysis, Cytel's clinical innovation know- how is unmatched.

At this year's DIA meeting, senior managers, clinicians, statisticians and trial logistics professionals from the biopharmaceutical industry will share their recent experiences with adaptive trials, and the insights gained on planning and conducting the next generation of adaptive studies.

Speaking on the latest innovative trial techniques and tools will be Cytel Co-Founder and President, Dr. Cyrus Mehta, and Vice President of Adaptive Trials, Judith Quinlan.

Dr. Mehta will join Dr. William Byrom, Vice President, Product Strategy at trial technology leader ClinPhone, for the workshop "Adaptive Design in Clinical Research", June 23, 10:30A - 12:30P.

Reporting on the PhRMA Working Group for Adaptive Trials efforts to chronicle trial innovation successes, Cytel's Judith Quinlan presents "Are You Ready for Adaptive Clinical Development? Examples, Case Studies, Successes" on June 24, 8:30A - 9:30A.
See the complete DIA meeting website

http://www.diahome.org/DIAHome/FlagshipMeetings/home.aspx?meetingid=14235

and the DIA's blog site

http://www.diaannual.com/

Dr. Mehta and Vice President Quinlan are available for interviews following the DIA conference.


'/>"/>
SOURCE Cytel, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):